Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
NEW YORK, April 01, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Rockwell Medical, Inc. securities (NASDAQ:RMTI) from September 9, 2015 through February 29, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Rockwell Medical investors under the federal securities laws.
To join the Rockwell Medical class action, go to the firm’s website at http://rosenlegal.com/cases-847.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the primary product offering for Triferic will be in a powder packet packaging, which the FDA has not yet approved; (2) Rockwell Medical is seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement; and (3) as a result, defendants’ statements about Rockwell Medical’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-847.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
